

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-167 (cancelled).

168 (currently amended). A method of effecting ~~change in the surface antigens~~ expressed by incorporating a synthetic molecule construct of the structure F-S₁-S₂-L into the lipid bi-layer of a cell or a multi-cellular structure ~~comprising~~ including the step of:

of contacting a suspension of the cell or multi-cellular structure with a the synthetic molecule construct of the structure F-S₁-S₂-L for a time and at a temperature sufficient to effect the change; allow incorporation where:


F is a glycoepitope mono-, di-, tri- or oligo- saccharide;

S₁ is a C₃₋₅-aminoalkyl selected from the group consisting of: 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl;

S₂ is selected from the group consisting of: -CO(CH₂)₂CO-, -CO(CH₂)₃CO-, -CO(CH₂)₄CO- (adipate) and or -CO(CH₂)₅CO-; and

L is a lipid selected from the group consisting of diacyl- and or dialkyl-glycerophospholipids.

169 (currently amended). The method according to claim 168 where the construct includes the substructure:



where:

$n = 3$ to 5 , and M is H or a monovalent cation selected from the group consisting of Na^+ , K^+ or NH_4^+ , and $*$ is other than H .

170 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is of human or murine origin.

171 (previously presented). The method according to claim 168 where the concentration of the construct in the suspension is in the range 0.1 to 10 mg/mL.

172 (previously presented). The method according to 168 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 37 °C.

173 (previously presented). The method according to claim 172 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 25 °C.

174 (previously presented). The method according claim 173 where the suspension of the cell or multi-cellular structure is contacted with the construct at a

temperature in the range 2 to 4 °C.

175 (previously presented). The method according to claim 168 where F is selected from the group consisting of GalNAc α 1-3(Fuc α 1-2)Gal β ; Gal α 1-3Gal β ; Gal β ; Gal α 1-3(Fuc α 1-2)Gal β ; NeuAc α 2-3Gal β ; NeuAc α 2-6Gal β ; Fuc α 1-2Gal β ; Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(Fuc α 1-2Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; NeuAc α 2-3Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; Gal α 1-4Gal β 1-4Glc; GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; GalNAc α 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; and GalNAc β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc.


176 (currently amended). The method according to claim 175 where F is selected from the group consisting of the oligosaccharides GalNAc α 1-3(Fuc α 1-2)Gal β and Gal α 1-3(Fuc α 1-2)Gal β .

177 (previously presented). The method according to claim 168 where S₁ is 3-aminopropyl.

178 (previously presented). The method according to claim 168 where L is selected from the group consisting of: 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE).

179 (withdrawn—currently amended). The method according to claim 168


where the construct is:



designated A_{tri}-sp-Ad-DOPE (I).


180 (withdrawn—currently amended). The method according to claim 168

where the construct is:



designated A_{tri}-sp-Ad-DSPE (III).


181 (withdrawn—currently amended). The method according to claim 168
 where the construct is:



designated B_{tri}-sp-Ad-DOPE (VI).


182 (withdrawn—currently amended). The method according to claim 168


where the construct is:



designated H_{Iri}-sp-Ad-DOPE (VII).


183 (withdrawn—currently amended). The method according to claim 168
 where the construct is:






designated H_d-sp-Ad-DOPE (VIII).


184 (withdrawn). The method according to claim 168 where the construct is:



designated Galβ-sp-Ad-DOPE (IX).


185 (withdrawn—currently amended). The method according to claim 168 where the construct is:






designated $\text{Fuca}1\text{-}2\text{Gal}\beta 1\text{-}3\text{GlcNAc}\beta 1\text{-}3\text{Gal}\beta 1\text{-}4\text{GlcNAc-sp-Ad-DOPE}$ (XII).

186 (withdrawn—currently amended). The method according to claim 168
 where the construct is:





designated Fuca1-2Galβ1-3(Fuca1-4)GlcNAc-sp-Ad-DOPE (XIII).

187 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is a red blood cell.

188-189 (cancelled).